Floatz logo

XK 469

Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

98 Active assets in the Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Pevonedistat
Takeda
Phase 3BB
Venetoclax
Servier Bio-Innovation LLC
Phase 2/3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Evomela
City of Hope Medical Center
Phase 2BB
Azacitidine
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

XK 469 is also rated in:

acute myeloid leukemia with minimal differentiationDormant
CC
Indicative ·
47 / 100
View asset →
acute monocytic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
acute basophilic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →